Questioning a South African hypertension threshold of 150 mm Hg

Authors’ reply
We are grateful for the opportunity to respond to Schutte and colleagues. We agree with Schutte and colleagues that the systolic blood pressure (SBP) measurements presented in our study could contain error.1 However, of the potential sources of measurement error they note (white-coat effects [+2·5 mm Hg], averaging measurements from two different waves [+3·8 mm Hg], and supine measurements [+3·10 mm Hg]), only the white-coat effects potentially applies to our study. Although we average measurements from 2 different years, we assign the resulting SBP to the last year of data. Therefore, any bias would result in SBP measurements that are conservative, rather than inflated by 3·5 mm Hg. Therefore, any bias would result in SBP measurements that are conservative, rather than inflated by 3·5 mm Hg. Accordingly, our study is conservative; however, Schutte and colleagues correctly identified our reporting error, and we have requested a formal correction. On balance, any measurement error is likely to be much smaller than Schutte and colleagues assert and would not change our main study conclusions.

Schutte and colleagues argue that all-cause mortality is a flawed outcome because it ignores the effect of SBP control on outcomes such as stroke. Although we agree that further studies are needed to compare the effect of different SBP thresholds with other outcomes, all-cause mortality is a fundamental outcome for assessing health interventions and is commonly used in cardiovascular intervention trials and large-scale observational studies.3 4 Thus, we believe that presenting evidence using all-cause mortality is important for guiding decisions on how to provide hypertension care in South Africa.

We also agree with Schutte and colleagues that clinical guidelines should not be changed based on one observational study. However, there are currently no clinical trials comparing different SBP thresholds using a South African population; therefore, there is no definitive evidence on which to base guideline decisions. Clinical trial estimates are only unbiased for their study population and could be biased when applied to different contexts,5 casting doubt on whether the 140/90 mm Hg threshold can be exported from other populations to South Africa. For this reason, we believe that our paper creates a valuable starting point for informing care decisions by providing one of the first studies on the longitudinal relationship between SBP and mortality in South Africa using national data. We do not share Schutte and colleagues’ view that presenting such evidence is irresponsible and rather believe that it can spur thoughtful open discussion on the best policy options given the country’s epidemiological profile and resources.

We declare no competing interests.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

*Nikkil Sudharsanan, Alpha Oumar Diallo, Mohammed K Ali, Pascal Geldsetzer, Emily W Gower, Trasias Mukama, Ryan G Wagner, Justine Davies, Maarten J Bijlsma
nikkil.sudharsanan@uni-heidelberg.de

Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany (NS, PG, TM); Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA (AOD, EWG); Hubert Department of Global Health, Rollins School of Public Health, and Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, GA, USA (MKKA); Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, USA (PG); Department of Disease Control and Environmental Health, Makenne University School of Public Health, Kampala, Uganda (TM); MRC/WTs Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, University of Witwatersrand, Johannesburg, South Africa (RGW, JD); Institute of Applied Health Research, University of Birmingham, Birmingham, UK (JD); Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape Town, South Africa (JD); Max Planck Institute for Demographic Research, Rostock, Germany (MB); Groningen Research Institute of Pharmacy, Unit Pharmacotherapy, Epidemiology & Economics, University of Groningen, the Netherlands (MJ)